6. 诺华公司

    • 2013年研发支出：99亿美元

    • 占收入的百分比：16.8%

    诺华公司（Novartis）的研发投入规模在医疗保健行业位居第二。2013年，研发支出占该公司收入的比重接近17%。诺华有200多个项目处于临床开发阶段，其中138个是药物项目。Zykadia是该公司的重大研发成果之一，这是一种选择性间变性淋巴瘤激酶抑制剂，用于治疗肺癌。诺华8月份所公布的心力衰竭临床试验药物LCZ696的数据显示，该药疗效好于目前的最佳治疗手段。今年10月，美国食品药品监督管理局（FDA）顾问委员会全票支持批准将诺华新药AIN457（secukinumab）用于治疗中重度牙菌斑。

    6. Novartis

    • R&D spending in 2013: $9.9 billion

    • As a percentage of revenue: 16.8%

    As the second-biggest health care spender, Novartis invested nearly 17% of its revenues into R&D in 2013 and has more than 200 projects in clinical development, including 138 in pharmaceuticals. Among the big discoveries from its R&D program was the drug Zykadia, which treats patients with a certain form of lung cancer called anaplastic lymphoma and, in August, the company presented data on its drug LCZ696, an investigational heart failure medicine, showing it was superior to the current best treatments. And in October, an advisory committee to the FDA approved unanimously to support the approval AIN457 (secukinumab) for the treatment of moderate-to-severe dental plaque.